Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

450
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
450
Angina IV: Management01:26

Angina IV: Management

495
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
495
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

659
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
659

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Pilot feasibility study of intraprocedural transcranial Doppler monitoring to assess Heal coating thrombogenicity in flow diversion.

Frontiers in neurology·2026
Same author

MAD-MT Score: A Tool to Optimize Patient Selection for Mechanical Thrombectomy in Distal Vessel Occlusions.

Stroke·2026
Same author

Clopidogrel versus ticagrelor in dual antiplatelet therapy for flow diversion of unruptured intracranial aneurysms: analysis of the Neurovascular Quality Initiative-Quality Outcomes Database (NVQI-QOD) Cerebral Aneurysm Registry.

Journal of neurointerventional surgery·2026
Same author

Distinct Clinical Phenotypes in Moyamoya Disease: A Multicenter Comparison of Ischemic and Hemorrhagic Presentations.

Neurosurgery·2026
Same author

International multi-center study to quantify the effect of deep venous drainage after surgical resection of Spetzler-Martin Grade II-III brain arteriovenous malformations.

Neurosurgical review·2026
Same author

Woven Endobridge device for ruptured vs. unruptured aneurysms: insights from the WorldWideWEB study.

Neuroradiology·2026

関連する実験動画

Updated: May 6, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.7K

現代における動脈再循環:動脈内膜切除術,動脈血管整形術およびステント,動脈経再循環の比較レビュー

Abdelaziz Amllay1, Andrew B Koo1, Daniela Renedo1

  • 1Department of Neurosurgery, Yale University, Yale-New Haven Hospital, New Haven, Connecticut, United States.

Seminars in neurology
|September 1, 2025
PubMed
まとめ

頸動脈の狭窄は脳卒中のリスクを高めます 動脈末端切除術 (CEA),動脈輸血術 (TF-CAS),および動脈経再血管化 (TCAR) は選択肢であり,TCARは有望である.

さらに関連する動画

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K
A Magnetic Resonance Imaging-based Computational Protocol for Analysis of Plaque Morphology and Hemodynamics in Patients with Carotid Artery Stenosis
09:36

A Magnetic Resonance Imaging-based Computational Protocol for Analysis of Plaque Morphology and Hemodynamics in Patients with Carotid Artery Stenosis

Published on: August 12, 2025

67

関連する実験動画

Last Updated: May 6, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.7K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K
A Magnetic Resonance Imaging-based Computational Protocol for Analysis of Plaque Morphology and Hemodynamics in Patients with Carotid Artery Stenosis
09:36

A Magnetic Resonance Imaging-based Computational Protocol for Analysis of Plaque Morphology and Hemodynamics in Patients with Carotid Artery Stenosis

Published on: August 12, 2025

67

科学分野:

  • 血管 外科
  • 神経科学
  • 介入心臓科

背景:

  • 頸動脈の狭窄は 血性脳卒中の主要な原因です
  • ガイドラインでは,症状性狭窄症 ≥50%および無症状性狭窄症 ≥70%に対する介入が推奨されています.
  • 最適な治療は不可欠ですが 特定の患者に手術は不可欠です

研究 の 目的:

  • 現在の頸動脈再血管化の戦略を比較的に検討する.
  • 臨床的徴候,外科的技法,結果を分析する.
  • 治療の選択のための個別化されたリスク・利益評価を基にします.

主な方法:

  • 既存の証拠を比較する
  • 頸動脈末関節切除 (CEA),頸動脈輸血術およびステント (TF-CAS),および頸動脈横関節再血管化 (TCAR) に関するデータの分析
  • 安全性と有効性の評価

主要な成果:

  • CEAは 頸動脈再血管化の ゴールドスタンダードです
  • TF-CASとTCARは高リスク患者にとって安全な代替品です.
  • TCARはCEAに匹敵する安全性と有効性を示し,特定の患者ではTF- CASに優れている可能性があります.

結論:

  • 治療の選択には 多学科で個別化されたリスク・利益の評価が必要です
  • TCARは新興で効果的な 頸動脈再血管化の選択肢です
  • TCARはCEAの有効な代替品であり,TF-CASに優れている可能性があるという証拠があります.